Species differences in oxidative metabolism of regorafenib

References

• Aiba I, Yamasaki T, Shinki T, Izumi S, Yamamoto K, Yamada S, Terato H, Ide H, Ohyama Y. 2006. Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 71(10):849–856.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al. 2017. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 389(10064):56–66.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang Y-K, Blay J-Y, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, et al. 2013. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID); an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381(9863):295–302.
   PubMed Web of Science ®Google Scholar
• Drozdzik M, Busch D, Lapczuk J, Müller J, Ostrowski M, Kurzawski M, Oswald S. 2018. Protein abundance of clinically relevant drug-metabolizing enzymes in the human liver and intestine: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 104(3):515–524.
   PubMed Web of Science ®Google Scholar
• Gerisch M, Hafner F-T, Lang D, Radtke M, Diefenbach K, Cleton A, Lettieri J. 2018. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects. Cancer Chemother Pharmacol. 81(1):195–206.
   PubMed Web of Science ®Google Scholar
• Ghassabian S, Gillani TB, Rawling T, Crettol S, Nair PC, Murray M. 2019. Sorafenib N-oxide is an inhibitor of human hepatic CYP3A4. Aaps J. 21(2):15.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, CORRECT Study Group, et al. 2013. Regorafenib monotherapy for previous treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-contralled, phase 3 trial. Lancet. 381(9863):303–312.
   PubMed Web of Science ®Google Scholar
• Hernandez D, Janmohamed A, Chandan P, Phillips IR, Shephard EA. 2004. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics. 14(2):117–130.
   PubMedGoogle Scholar
• Iwasaki K, Murayama N, Koizumi R, Uno Y, Yamazaki H. 2010. Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans. Drug Metab Pharmacokinet. 25(4):388–391.
   PubMed Web of Science ®Google Scholar
• Kotegawa T, Laurijssens BE, von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, Greenblatt DJ, et al. 2002. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther. 302(3):1228–1237.
   PubMed Web of Science ®Google Scholar
• Kubota Y, Fujita K‐i, Takahashi T, Sunakawa Y, Ishida H, Hamada K, Ichikawa W, Tsunoda T, Shimada K, Masuo Y, et al. 2020. Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients. Clin Pharmacol Ther. 108(3):586–595.
   PubMed Web of Science ®Google Scholar
• Matsubara T, Kim HJ, Miyata M, Shimada M, Nagata K, Yamazoe Y. 2004. Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J Pharmacol Exp Ther. 309(3):1282–1290.
   PubMed Web of Science ®Google Scholar
• Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. 2006. The human intestinal cytochrome P450 "pie. Drug Metab Dispos. 34(5):880–886.
   PubMed Web of Science ®Google Scholar
• Perloff MD, Von Moltke LL, Greenblatt DJ. 2003. Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression. Xenobiotica. 33(4):365–377.
   PubMed Web of Science ®Google Scholar
• Phillips IR, Shephard EA. 2017. Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 13(2):167–181.
   PubMed Web of Science ®Google Scholar
• Rich KJ, Sesardic D, Foster JR, Davies DS, Boobis AR. 1989. Immunohistochemical localization of cytochrome P450b/e in hepatic and extrahepatic tissues of the rat . Biochem Pharmacol. 38(19):3305–3322.
   PubMed Web of Science ®Google Scholar
• Roberts AG, Atkins WM. 2007. Energetics of heterotropic cooperativity between alpha-naphthoflavone and testosterone binding to CYP3A4. Arch Biochem Biophys. 463(1):89–101.
   PubMed Web of Science ®Google Scholar
• Sakakibara Y, Katoh M, Kawayanagi T, Nadai M. 2016. Species and tissue differences in serotonin glucuronidation. Xenobiotica. 46(7):605–611.
   PubMed Web of Science ®Google Scholar
• Schroeder B, Li Z, Cranmer LD, Jones RL, Pollack SM. 2016. Targeting gastrointestinal stromal tumors: the role of regorafenib. Onco Targets Ther. 9:3009–3016.
   PubMed Web of Science ®Google Scholar
• Sesardic D, Cole KJ, Edwards RJ, Davies DS, Thomas PE, Levin W, Boobis AR. 1990. The inducibility and catalytic activity of cytochromes P450c (P450IA1) and P450d (P450IA2) in rat tissues. Biochem Pharmacol. 39(3):499–506.
   PubMed Web of Science ®Google Scholar
• Uehara S, Murayama N, Nakanishi Y, Nakamura C, Hashizume T, Zeldin DC, Yamazaki H, Uno Y. 2014. Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys. Xenobiotica. 44(9):769–774.
   PubMed Web of Science ®Google Scholar
• Uehara S, Murayama N, Nakanishi Y, Zeldin DC, Yamazaki H, Uno Y. 2011. Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. J Pharmacol Exp Ther. 339(2):654–661.
   PubMed Web of Science ®Google Scholar
• Uehara S, Murayama N, Nakanishi Y, Nakamura C, Hashizume T, Zeldin DC, Yamazaki H, Uno Y. 2015. Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine. Xenobiotica. 45(2):124–130.
   PubMed Web of Science ®Google Scholar
• Uno Y, Hosaka S, Matsuno K, Nakamura C, Kito G, Kamataki T, Nagata R. 2007. Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism? Arch Biochem Biophys. 466(1):98–105.
   PubMed Web of Science ®Google Scholar
• Uno Y, Iwasaki K, Yamazaki H, Nelson DR. 2011. Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev. 43(3):346–361.
   PubMed Web of Science ®Google Scholar
• Wang H, Dick R, Yin H, Licad-Coles E, Kroetz DL, Szklarz G, Harlow G, Halpert JR, Correia MA. 1998. Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry. 37(36):12536–12545.
   PubMed Web of Science ®Google Scholar
• Wang Y-K, Xiao X-R, Xu K-P, Li F. 2018. Metabolic profiling of the anti-tumor drug regorafenib in mice. J Pharm Biomed Anal. 159:524–535.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch K-H, Zopf D. 2011. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 129(1):245–255.
   PubMed Web of Science ®Google Scholar
• Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw CR, Zeldin DC, et al. 1997. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem. 272(19):12551–12559.
   PubMed Web of Science ®Google Scholar
• Xue Y, Li J, Wu Z, Liu G, Tang Y, Li W. 2019. Computational insights into the different catalytic activities of CYP3A4 and CYP3A5 toward schisantherin E. Chem Biol Drug Des. 93(5):854–864.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Okayama A, Imai N, Guengerich FP, Shimizu M. 2006. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica. 36(12):1201–1209.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 138(1):103–141.
   PubMed Web of Science ®Google Scholar
• Zopf D, Fichtner I, Bhargava A, Steinke W, Thierauch K-H, Diefenbach K, Wilhelm S, Hafner F-T, Gerisch M. 2016. Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. Cancer Med. 5(11):3176–3185.
   PubMed Web of Science ®Google Scholar